Azitra is a clinical stage biotech company focused on developing innovative therapies for precision dermatology. The Company's lead product, ATR-12, is an engineered strain of S. epidermidis to treat Netherton syndrome (NS), a rare, chronic skin disease with no approved treatment options. NS is often fatal in infancy with those living beyond a year having profound lifelong challenges. ATR-12 is being evaluated in a Phase 1b clinical trial in adult NS patients. ATR-04, Azitra's second product, is being developed for the treatment of EGFR inhibitor ("EGFRi") associated rash, which impacts ~150,000 people in the U.S. Azitra has an open IND for a Phase 1/2 clinical trial with ATR-04 in patients with EGFRi associated rash. ATR-12 and ATR-04 were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products. The platform is augmented by technologies that analyze, predict, and help screen the library of strains for drug-like molecules.